Vitiligo Drugs Market, by Drug Class, by Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Vitiligo is a disease that causes loss of skin colour in patches. The discoloured areas usually get bigger with time. The condition usually affects the skin on any part of the body. It can also affect hair and the inside of the mouth. The colour of hair and skin is determined by melanin. Melanin is a natural skin pigment; skin, eye, and hair color in people and animal depends on type and amount of melanin. Vitiligo occurs, when cells that produce melanin stop functioning. The condition is not life- threatening or transferable. There are two major categories of vitiligo disease such as segmental vitiligo and non-segmental vitiligo. Some of the major symptoms of vitiligo disease includes patchy loss of skin colour, which mostly appears on hands and face. Premature whitening of the hair on your scalp or eyebrows. Loss in the colour inside the mouth. Vitiligo disease can be treated by medications such as calcineurin inhibitors, corticosteroids, Psoralens. Vitiligo disease is also treated by surgery.

Market Dynamics

Agreement and collaboration by major players to develop drug is expected to propel growth of the global vitiligo drug market during the forecast period. For instance, in October 2018, Boston Pharmaceutical announced the agreement with GlaksoSmith Kline for development of phase 1 pipeline drug GSK3183475, a small molecule inhibitor used in treatment of vitiligo and psoriasis.

However, alternative therapies for vitiligo treatment is expected to limit the market growth. For instance, combination therapy of psoralen and light therapy. The treatment combines the use of a plant- derived molecule called psoralen and light therapy for treating vitiligo. The patient is exposed to ultraviolet light after ingesting psoralen. The total span of treatment ranges between 3 weeks to 12 months.

Key features of the study:

• This report provides in-depth analysis of the global vitiligo drug market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022 - 2028), considering 2021 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global lung cancer screening market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Dermavant Sciences, Inc., Incyte Corporation, Aclaris Therapeutics, Inc., Dr. Reddy's Laboratories Ltd., Bristol- Myers Squibb, Pfizer, Inc., Clinuvel Pharmaceuticals Ltd., Boston Pharmaceuticals, Applied Biology, Inc., Arcutis Biotherapeutics, Villaris Therapeutics, Arrien Pharmaceuticals LLC, and Temprian Therapeutics Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global vitiligo drug market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for vitiligo drug market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

• Global Vitiligo Drug Market, By Drug Type:
• Marketed Drugs

? Calcineurin Inhibitors

? Corticosteroids

? Psoralens

• Pipeline Drug

? Ruxolitinib (Phase 3)

• Global Vitiligo Drug Market, By Indication Type:
• Segmental Vitiligo
• Non-segmental Vitiligo
• Global Vitiligo Drug Market, By Route of Administration Type:
• Oral
• Topical
• Global Vitiligo Drug Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Vitiligo Drug Market, By Region:
• North America

? By Country:

? U.S.

? Canada

? By Drug Type:

? Marketed Drugs

? Calcineurin Inhibitors

? Corticosteroids

? Psoralens

? Pipeline Drug

? Ruxolitinib (Phase 3)

? By Indication Type:

? Segmental Vitiligo

? Non-segmental Vitiligo

? By Route of Administration

? Oral

? Topical

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

• Europe

? By Country:

? U.K.

? Germany

? Italy

? Spain

? France

? Russia

? Rest of Europe

? By Drug Type:

? Marketed Drugs

? Calcineurin Inhibitors

? Corticosteroids

? Psoralens

? Pipeline Drug

? Ruxolitinib (Phase 3)

? By Indication Type:

? Segmental Vitiligo

? Non-segmental Vitiligo

? By Route of Administration

? Oral

? Topical

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

• Asia Pacific

? By Country:

? Australia

? India

? China

? Japan

? ASEAN

? South Korea

? Rest of Asia Pacific

? By Drug Type:

? Marketed Drugs

? Calcineurin Inhibitors

? Corticosteroids

? Psoralens

? Pipeline Drug

? Ruxolitinib (Phase 3)

? By Indication Type:

? Segmental Vitiligo

? Non-segmental Vitiligo

? By Route of Administration

? Oral

? Topical

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

• Latin America

? By Country:

? Brazil

? Mexico

? Argentina

? Rest of Latin America

? By Drug Type:

? Marketed Drugs

? Calcineurin Inhibitors

? Corticosteroids

? Psoralens

? Pipeline Drug

? Ruxolitinib (Phase 3)

? By Indication Type:

? Segmental Vitiligo

? Non-segmental Vitiligo

? By Route of Administration

? Oral

? Topical

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

• Middle East

? By Country:

? GCC

? Israel

? Rest of Middle East

? By Drug Type:

? Marketed Drugs

? Calcineurin Inhibitors

? Corticosteroids

? Psoralens

? Pipeline Drug

? Ruxolitinib (Phase 3)

? By Indication Type:

? Segmental Vitiligo

? Non-segmental Vitiligo

? By Route of Administration

? Oral

? Topical

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

• Africa

? By Country/Region:

? South Africa

? Central Africa

? North Africa

? By Drug Type:

? Marketed Drugs

? Calcineurin Inhibitors

? Corticosteroids

? Psoralens

? Pipeline Drug

? Ruxolitinib (Phase 3)

? By Indication Type:

? Segmental Vitiligo

? Non-segmental Vitiligo

? By Route of Administration

? Oral

? Topical

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

• Company Profiles
• Dermavant Sciences, Inc.*

? Company Overview

? Product Portfolio

? Financial Performance

? Recent Highlights

? Strategies

• Incyte Corporation
• Aclaris Therapeutics, Inc
• Reddy's Laboratories Ltd.
• Bristol - Myers Squibb
• Pfizer, Inc.
• Clinuvel Pharmaceuticals Ltd.
• Boston Pharmaceuticals
• Applied Biology, Inc.
• Arcutis Biotherapeutics
• Villaris Therapeutics
• Arrien Pharmaceuticals LLC
• Temprian Therapeutics Inc.

"*" marked represents similar segmentation in other categories in the respective section.